Loading clinical trials...
Loading clinical trials...
A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis
Conditions
Interventions
VSN16R
Placebo
Locations
4
United Kingdom
The Neuroscience Research Centre, The Walton Centre NHS Foundation Trust
Liverpool, United Kingdom
The Royal London Hospital
London, United Kingdom
The National Hospital for Neurology and Neurosurgery
London, United Kingdom
Royal Hallamshire Hospital, Sheffield Teaching Hospital NHS Foundation Trust
Sheffield, United Kingdom
Start Date
August 1, 2015
Primary Completion Date
October 1, 2017
Completion Date
October 1, 2017
Last Updated
March 2, 2018
Lead Sponsor
Canbex Therapeutics Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions